The Future of Genomic Profiling of Neurological Diseases Using Blood.
Frank R. Sharp,Huichun Xu,Lisa Lit,Wynn L. Walker,Michelle Apperson,Donald L. Gilbert,Tracy A. Glauser,Brenda Wong,Andrew D. Hershey,Da Zhi Liu,Joseph D. Pinter,Xinhua Zhan,Xinshe Liu,Ruiqiong Ran
DOI: https://doi.org/10.1001/archneur.63.11.1529
2006-01-01
Archives of Neurology
Abstract:Sequencing of the human genome and new microarray technology make it possible to assess all genes on a single chip or array. Recent studies show different patterns of gene expression related to different tissues and diseases, and these patterns of gene expression are beginning to be used for diagnosis and treatment decisions in various types of lymphoid and solid malignancies. Because of obvious problems obtaining brain tissue, progress in genomics of neurological diseases has been slow. To address this, we demonstrated that different types of acute injury in rodent brain produced different patterns of gene expression in peripheral blood. These animal studies have now been extended to human studies. Two groups have shown that there are specific genomic profiles in the blood of patients after ischemic stroke that are highly sensitive and specific for predicting stroke. Other recent studies demonstrate specific genomic profiles in the blood of patients with Down syndrome, neurofibromatosis, tuberous sclerosis, Huntington disease, multiple sclerosis, Tourette syndrome, and others. In addition, data demonstrate specific profiles of gene expression in the blood related to different drugs, toxins, and infections. Although all of these studies are still preliminary basic scientific endeavors, they suggest that this approach will have clinical applications to neurological diseases in humans.